2024
Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealing
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDisease
2019
Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Park S, Al-Bawardy B, Aniwan S, Kane S, Coelho-Prabhu N, Papadakis K, Kisiel J, Bruining D, Faubion W, Raffals L, Pardi D, Tremaine W, Stephens M, Tung J, Khanna S, Willrich M, Loftus E. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019, 1: otz047. DOI: 10.1093/crocol/otz047.Peer-Reviewed Original ResearchAdalimumab trough levelsRadiologic responseDisease activityTrough levelsReferral center-based cohortInflammatory bowel disease patientsRadiologic disease activityBowel disease patientsInflammatory bowel diseaseC-reactive proteinDifferent therapeutic outcomesHigher cutoff levelsBowel diseaseDisease patientsCutoff levelTherapeutic outcomesCutoff valuePatientsCohortIBDLevelsDiseaseResponse
2018
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/